Literature DB >> 1579042

Human cytochrome P-450 enzymes.

F P Guengerich1.   

Abstract

Cytochrome P-450 (P-450) enzymes have been studied extensively in experimental animal models and much is known regarding their structures, regulation, and mechanisms of catalysis. In recent years investigations have been extended to the human P-450s. There are more than 30 different characterized human P-450s in the superfamily, and collectively they are probably the most significant enzymes involved in the metabolism of drugs, carcinogens, and steroids. The levels of many of the P-450s and their catalytic activities can vary considerably because of polymorphism, induction, and inhibition. The catalytic specificity of the P-450s can range from being very non-discriminatory to very exacting, and clinical consequences of drugs and steroids can be related to variations in P-450 levels. Defects in the rate-limiting P-450 reactions in steroidogenesis (due to genetic deficiencies) have been shown to be debilitating and even fatal.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1579042     DOI: 10.1016/0024-3205(92)90136-d

Source DB:  PubMed          Journal:  Life Sci        ISSN: 0024-3205            Impact factor:   5.037


  16 in total

1.  Inhibition of cytochrome P450 2B4 by environmentally persistent free radical-containing particulate matter.

Authors:  James R Reed; Albert Leo N dela Cruz; Slawo M Lomnicki; Wayne L Backes
Journal:  Biochem Pharmacol       Date:  2015-03-24       Impact factor: 5.858

Review 2.  Cytochrome P450 Organization and Function Are Modulated by Endoplasmic Reticulum Phospholipid Heterogeneity.

Authors:  Lauren M Brignac-Huber; Ji Won Park; James R Reed; Wayne L Backes
Journal:  Drug Metab Dispos       Date:  2016-05-27       Impact factor: 3.922

3.  Environmentally persistent free radical-containing particulate matter competitively inhibits metabolism by cytochrome P450 1A2.

Authors:  James R Reed; Albert Leo N dela Cruz; Slawo M Lomnicki; Wayne L Backes
Journal:  Toxicol Appl Pharmacol       Date:  2015-09-28       Impact factor: 4.219

4.  A discordance of the cytochrome P450 2C19 genotype and phenotype in patients with advanced cancer.

Authors:  M L Williams; P Bhargava; I Cherrouk; J L Marshall; D A Flockhart; I W Wainer
Journal:  Br J Clin Pharmacol       Date:  2000-05       Impact factor: 4.335

Review 5.  Clinically significant interactions of psychotropic agents with antipsychotic drugs.

Authors:  M C Meyer; R J Baldessarini; D C Goff; F Centorrino
Journal:  Drug Saf       Date:  1996-11       Impact factor: 5.606

Review 6.  Extrahepatic metabolism of drugs in humans.

Authors:  D R Krishna; U Klotz
Journal:  Clin Pharmacokinet       Date:  1994-02       Impact factor: 6.447

7.  Extrahepatic metabolism of frusemide in anaesthetized rabbits.

Authors:  J Vergés; L Héroux; H Maurice; P du Souich
Journal:  Br J Pharmacol       Date:  1995-11       Impact factor: 8.739

8.  Cytochrome P450 1B1 mRNA in the human central nervous system.

Authors:  C R Rieder; D B Ramsden; A C Williams
Journal:  Mol Pathol       Date:  1998-06

9.  Risk of coronary artery disease associated with polymorphism of the cytochrome P450 epoxygenase CYP2J2.

Authors:  Martin Spiecker; Harald Darius; Thomas Hankeln; Muhidien Soufi; Alexander M Sattler; Jürgen R Schaefer; Koichi Node; Jan Börgel; Andreas Mügge; Klaus Lindpaintner; Anika Huesing; Bernhard Maisch; Darryl C Zeldin; James K Liao
Journal:  Circulation       Date:  2004-10-04       Impact factor: 29.690

10.  Inhibitors of alprazolam metabolism in vitro: effect of serotonin-reuptake-inhibitor antidepressants, ketoconazole and quinidine.

Authors:  L L von Moltke; D J Greenblatt; M M Cotreau-Bibbo; J S Harmatz; R I Shader
Journal:  Br J Clin Pharmacol       Date:  1994-07       Impact factor: 4.335

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.